{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:22:09Z","timestamp":1771867329791,"version":"3.50.1"},"reference-count":19,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1701,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1111\/j.1365-2710.2009.01153.x","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T22:12:43Z","timestamp":1276207963000},"page":"19-26","source":"Crossref","is-referenced-by-count":26,"title":["Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study"],"prefix":"10.1155","volume":"36","author":[{"given":"X.","family":"Armoiry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fagnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Benboubker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Facon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Fermand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Aulagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple myeloma: diagnosis and treatment","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB3|cit3","unstructured":"Eucan Database 1998 http:\/\/www-dep.iarc.fr\/eucan\/eucan.htm"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","article-title":"Treatment of multiple myeloma","volume":"103","author":"Barlogie","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"1 Suppl. 3","key":"10.1111\/j.1365-2710.2009.01153.x-BIB8|cit8","first-page":"3","article-title":"Management of multiple myeloma today","volume":"36","author":"Anderson","year":"1999","journal-title":"Seminars in Hematology"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2005.05867.x","article-title":"Guidelines on the diagnosis and management of multiple myeloma 2005","volume":"132","author":"Smith","year":"2006","journal-title":"British Journal Haematology"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2710.2008.00920.x","article-title":"Lenalidomide in the treatment of multiple myeloma: a review","volume":"33","author":"Armoiry","year":"2008","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.ejca.2005.11.036","article-title":"An update: health economics of managing multiple myeloma","volume":"42","author":"Moeremans","year":"2006","journal-title":"European Journal of Cancer"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1532\/IJH97.A30512","article-title":"A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma","volume":"83","author":"Bang","year":"2006","journal-title":"International Journal of Hematology"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2008.99","article-title":"VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma","volume":"22","author":"Pineda-Roman","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/j.1365-2710.2009.01153.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.clinthera.2008.09.003","article-title":"Direct hospital resource utilization and costs of treating patients with multiple myeloma in southwest Sweden: a 5-year retrospective analysis","volume":"30","author":"Ghatnekar","year":"2008","journal-title":"Clinical Therapeutics"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2009.01153.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2009.01153.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:38Z","timestamp":1671818618000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2009.01153.x"}},"subtitle":["Management of relapsed or refractory multiple myeloma in French hospitals"],"short-title":[],"issued":{"date-parts":[[2011,1,4]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01153.x","relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1,4]]}}}